abstract: Various cytokines derived from placental cells are essential for normal placenta development and successful pregnancy. Interleukin-6 (IL-6) is a multifunctional cytokine produced by extravillous and cytotrophoblasts regulating the functions of these cells, e.g. migration, invasion, trophoblast differentiation and proliferation. In macrophages, newly synthesized IL-6 accumulates in the Golgi complex and exits in tubulovesicular carriers fused with recycling endosomes and secreted as a soluble protein. Sphingosine-1-phosphate (S1P) induces various cytokine secretions including IL-6 in different cell types. The signaling mechanisms regulating the IL-6 secretion are unknown. In this study, we found that S1PR 2 was the major S1P receptor being expressed in BeWo cells. S1P regulated IL-6 protein secretion in early phase (6 h) and gene expression in later phase (24 h). IL-6 secretion was completely inhibited via inhibitor of transcription (Actinomycin D) or protein synthesis (Cycloheximide) confirming that IL-6 releases constitutively from BeWo cells. By using specific S1PR 2 inhibitor JTE-013 and S1PR 2 gene silencing, we found that S1PR 2 was the main receptor that regulates IL-6 secretion. Furthermore, S1P induced RhoGTPases-dependent pathways that are required for IL-6 secretion. Pretreatment of cells with specific Rho-kinase inhibitor (Y27632) and Rac1 inhibitor (NSC23766) drastically inhibited S1P-induced IL-6 secretion. By using a specific Phosphoinositide 3-kinase (PI3K) inhibitor (LY294002), we found that basal activity of PI3K was required for secretion but was independent of S1P/S1PR 2 axis activation. In summary, we report first time that binding of S1P to S1PR 2 activates multiple RhoGTPases-dependent pathways that coordinate with PI3K pathway for secretion of IL-6 in BeWo cells.
Introduction
Aberrant development of the placenta has been linked to first trimester miscarriage and different pregnancy-related pathologies, like preeclampsia and intrauterine growth restriction. A wide array of cytokines derived from placenta together with other locally produced growth factors are essential for normal placental development and successful pregnancy (Denison et al., 1998; Bowen et al., 2002) .
Interleukin-6 (IL-6) is a multifunctional cytokine with diverse biological functions, including immune regulation, inflammation, hematopoiesis and angiogenesis by modulating cell proliferation, differentiation, migration and apoptosis (Ishihara and Hirano, 2002; Naka et al., 2002; Prins et al., 2012) . Deregulation of IL-6 production has been shown in various diseases, including rheumatoid arthritis, systemic mastocytosis and malignant tumors (Wellby et al., 2001; Theoharides et al., 2002) . Elevated IL-6 is observed during recurrent miscarriage, pre-eclampsia and preterm delivery (Prins et al., 2012) . IL-6 is produced by a variety of cell types, including placental cells such as villous and extravillous trophoblasts, monocytes, epithelial cells, endothelial cells and various types of tumor cells (Bowen et al., 2002; Ishihara and Hirano, 2002) . IL-6 binds to a heterodimeric receptor consisting of IL-6a chain and the common cytokine receptor signaling component gp130 (Kishimoto et al., 1995) . IL-6 is involved in regulating trophoblast secretion, differentiation, migration, invasion and proliferation (Nishino et al., 1990; Bowen et al., 2002; Champion et al., 2012; Prins et al., 2012) . In placenta, IL-6 mRNA expression decreases during differentiation of cytotrophoblast cells into syncytiotrophoblasts (Stephanou et al., 1995; Noyola-Martinez et al., 2013) . Invasive trophoblast cells express higher IL-6 mRNA (Das et al., 2002) .
Cytokine secretion is a complex and tightly controlled process, and intracellular pathways regulating secretion are often uniquely tailored to each cytokine and cell type. IL-6 lacking the transmembrane domain is secreted directly as a soluble protein. In macrophages, newly synthesized IL-6 accumulates in the Golgi complex and exits in tubulovesicular carriers fused with recycling endosomes (Manderson et al., 2007) . The signaling pathways regulating the IL-6 secretion are unknown.
Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, is a bioactive signaling molecule that regulates various physiological and pathophysiological processes including cell growth, cellular trafficking, apoptosis, inflammation and cancer (Maceyka et al., 2012) . S1P acts through a family of five specific G protein-coupled receptors (S1PR 1 -5 ) that activate diverse downstream signaling pathways and is also an important intracellular messenger (Spiegel and Milstien, 2011; Maceyka et al., 2012) . Each S1P receptor couples to different G-proteins: S1PR 1 links to G i , S1PR 2 and S1PR 3 link to G i , G q and G 12/13 and S1PR 4 and S1PR 5 link to G i and G q (Ye, 2008) . Coupling of S1P receptors to G-proteins stimulates downstream signaling molecules including RhoGTPases (Rac and Rho), Phosphoinositide 3-kinase (PI3K) and phospholipase C (Ye, 2008; Spiegel and Milstien, 2011) . S1P has been shown to induce various cytokine secretion including IL-6 and IL-8 in different cell types (Kozawa et al., 1997; Oz-Arslan et al., 2006a; Oskeritzian et al., 2010) . S1PR 2 is involved in mast cell degranulation and cytokine secretion (Oskeritzian et al., 2010) , but the signaling mechanisms responsible for cytokine secretion via S1P/ S1PR 2 axis have not been identified.
In the present study, we asked whether S1P regulates the cytokine secretion in trophoblast cell line, if so, which signaling pathways are activated downstream of S1P/S1P receptor axis. We found that IL-6 was exclusively regulated via S1P-mediated S1PR 2 activation. IL-6 seems to be released through constitutive exocytosis secretory pathway. Activation of small RhoGTPases (Rho and Rac1)-dependent pathways by S1P is required for IL-6 secretion. Basal activity of PI3K is essential for IL-6 secretion, but it is independent of S1P/S1PR 2 axis activation.
Materials and Methods

Materials
Oligonucleotides were synthesized by Eurofins MWG Operon, Ebersberg, Germany. S1P, W140, W146 and SEW2871 were from Cayman Chemical Company, MI, USA. VPC23019, JTE-013 and NSC23766 were from Tocris Bioscience, Bristol, UK. LY294002 and Cycloheximide (CHX) were from Merck Millipore Chemicals, Darmstadt, Germany. Actinomycin D (ACD) was from USBiological, Massachusetts, USA. PD98059 was from Cell Signaling Technology (CST), Danvers, MA, USA. Y27632 was from Sigma-Aldrich GmbH, Munich, Germany. EDG5/S1PR 2 ON-TARGETplus SMARTpool siRNA was from Dharmacon RNAi Technologies, Thermo Fisher Scientific, Waltham, MA, USA. Human IL-6 ELISA DuoSet was from R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany.
Cell culture
BeWo cells were grown in complete growth medium (DMEM/F12 basal medium containing 5% FCS) in a humidified incubator at 5% CO 2 and 378C. HTR-8/SVneo cell line was obtained from human first trimester placenta explant cultures immortalized by SV40 large T antigen (Graham et al., 1993) . HTR-8/SVneo cells were grown in RPMI-1640 basal medium containing 5% FCS. Human umbilical vein endothelial cells (HUVECs) were obtained and cultured as described previously (Goyal et al., 2011 ). Cells were trypsinized and then cells (50 000 cells/well) were plated in 48-well plates. 24 h prior to cell stimulation, growth medium was replaced with factor-reduced medium (cell basal medium containing 5% charcoal-stripped FCS). Cells were stimulated with S1P (1 mM) or different agonists in serum-starved medium (basal medium with 0.5% charcoal-stripped FCS). Solvents (methanol, DMSO) were served as control.
S1PR 2 silencing
A pool of four S1PR 2 -specific siRNAs (30 pmol) or a pool of non-target siRNAs (30 pmol) were diluted in 100 ml basal medium per well of a 24-well plate, 1.5 ml Lipofectamine RNAiMAX was then added and incubated for 15 min at room temperature. BeWo cells (50 000 cells/500 ml complete growth medium) were plated in the same well and then cells were grown at 378C, and 5% CO 2 . After 24 h of transfection, growth medium was exchanged to factor-reduced medium.
Real-time PCR
Total RNA was isolated using peqGOLD TriFast TM reagent (Peqlab, Erlangen, Germany) following the manufacturers' protocol. First-strand cDNAs were synthesized with High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, Darmstadt, Germany) using random hexamer primers according to manufacturer's protocol.
Gene specific primers for semi-quantitative real-time PCR were designed using Primer Express 3.0 (Applied Biosystems) and primer-target specificity was checked using nucleotide BLAST program (http://blast. ncbi.nlm.nih.gov). For real-time PCR, SYBR Green PCR master mix (Applied Biosystems) was used according to the manufacturers' instructions. PCR was performed in duplicates on an ABI Prism 7300 (Applied Biosystems) with the following cycling program: 2 min at 508C, 10 min at 958C, 15 s at 958C and 1 min at 608C for a total of 40 cycles. PCR products were analyzed by thermal dissociation curve and by agarose gel electrophoresis to verify specific PCR product amplification. Data were normalized against the reference gene b-actin. The sequences of primers of IL-6 and b-actin gene are as follow:
Viable cell counting
Viable cells were counted using the CellTiter-Bluew assay (Promega GmbH, Mannheim, Germany) as per the manufacturer's instructions. Fluorescence was measured by using FLUOstar OPTIMA microplate reader (BMG LABTECH GmbH) set to 544 nm (excitation) and 590 nm (emission).
ELISA
Cell conditioned media were collected from 48-well plates and then cells in each well were counted using CellTiter-Bluew assay (see above). For quantification of IL-6 secretion, human IL-6 DuoSet ELISA kit was used according to the manufacturer's guidelines. The detection limits of the assays were 1.5 -300 pg/ml. Briefly, each well of 8-well strips was coated with capture antibody (1:180) overnight, washed with PBST (PBS containing 0.05% Tween 20). Strips were then incubated with 100 ml of cell conditioned medium for overnight at 48C. Next day, strips were washed with PBST and then incubated with detection antibody (1:180) S1PR 2 regulates IL-6 secretion in BeWo cells for 2 h followed by washing with PBST. Finally, Streptavidin-HRP working solution (1:200) was added in each well of strips incubated for 20 min in dark and then washed with PBST. Strips were then incubated with substrate solution (100 ml) for 10 -20 min at room temperature in the dark and reaction was stopped with a stop-solution (2N H 2 SO 4 ). Optical density of developed color was measured by using FLUOstar OPTIMA microplate reader (BMG LABTECH GmbH) set to 450 nm and 570 nm. Data were corrected by subtracting the values at 570 nm from the values at 450 nm. The data were normalized against cell count. Controls were treated as 100% in each experiment and then fold changes were calculated as % of control.
Western Blot
Unstimulated and stimulated BeWo cells were dissolved in an equal volume of 2× Laemmli buffer. Equal amounts of proteins in the samples were subjected to 12% SDS-PAGE and then transferred to PVDF membrane at 200 mA for 60 min at 48C using the Mini Trans-Blot electrophoresis cell (Bio-Rad GmbH, Munich, Germany). Membranes were blocked with 5% (w/v) nonfat milk and incubated with the respective primary and secondary antibodies. The dilutions of the primary antibodies were: Akt (pan) (C67E7) rabbit mAb (CST; 1:1000), Phospho-Akt (Ser473) (193H12) rabbit (CST; 1:1000), EDG1 (S1PR 1 ) rabbit monoclonal antidody (Epitomics Abcam company, Cambridge, UK; 1:10 000 dilution), EDG3 (S1PR 3 ) rabbit monoclonal antibody (Abcam company; 1:10 000 dilution), S1P2/EDG5 mouse monoclonal antibody (R&D Systems; 1:500 dilution) and b-actin mouse monoclonal antibody (Millipore; 1:10 000 dilution). The dilution of the secondary goat-anti-rabbit 800 antibody and goat-anti-mouse 680 antibody (LI-COR) was 1:10 000. Protein signal was detected using the Odyssey Infrared Imager with application Software 3.0.30 (LI-COR Biosciences GmbH, Bad Homburg, Germany).
Immunofluorescent staining and fluorescence microscopy
Cells grown in an 8-well LabTek II chamber slide (Nunc, Thermo Fisher Scientific) were washed and fixed with 3.7% formaldehyde in PBS for 10 min at room temperature and then washed briefly three times for 5 min with PBS. For permeabilization, the cells were incubated in PBS containing 0.2% TritonX100 (PBST) and Hoechst 33258 (10 mg/ml) for 20 min at room temperature followed by three times washing with PBS. Cells were then incubated with blocking solution (2% fatty acid free BSA in PBST) for 30 min at room temperature, washed three times with PBS and then incubated with anti-S1P2/EDG5 mouse monoclonal antibody (R&D Systems; 1:100 dilution in 2% fatty acid free BSA in PBST) for 1 h in humidified chamber. Cells were washed three times with PBS and incubated with Alexa Fluorw555 goat-anti-mouse secondary antibody (1:200 dilution in 2% fatty acid free BSA in PBST) for 45 min at room temperature and then washed three times. Cells were observed with a Zeiss Axio Observer fluorescence microscope.
Statistical analysis
Minimum three independent experiments with different passages of BeWo cells were performed. Each experiment was performed in quadruplicates. Statistical analysis was carried out with one-way or two-way analysis of variance, followed by the Tukey's multiple comparison tests that were performed using GraphPad PRISM version 6 software (GraphPad, La Jolla, CA, USA). The results are calculated as mean + SD, and data are shown as mean + SD. The results having P-values of ,0.05 were considered statistically significant. *, significant (P , 0.05); **, very significant (P , 0.01); ***, highly significant (P , 0.001); ****, extremely significant (P , 0.0001).
Results
Expression of S1P receptors mRNA in BeWo cells
To examine the expression of known S1P receptor subtypes (S1PR 1 -5 ) in BeWo cells, a widely accepted in vitro model for villous cytotrophoblasts (Orendi et al., 2011) , and HTR-8/SVneo cells, we measured the abundance of S1P receptor mRNAs by using semi-quantitative realtime PCR. Among all the S1P receptor subtypes, S1PR 2 is the only receptor that was highly expressed in BeWo cells (Fig. 1A, left panel) . The expressions of other S1P receptor subtypes (S1PR 1 and S1PR 3 -5 ) were 350-1000-fold less expressed in comparison with S1PR 2 in these cells (Fig. 1A, left panel) . In contrast, all S1P receptor subtypes mRNA except S1PR 4 were expressed in HTR-8/SVneo cells (Fig. 1A,  right panel) . The expression of S1P receptors proteins was also analyzed by Western blotting using S1PR 1 -3 specific antibodies. Anti-S1PR 1 and S1PR 3 specific antibodies could identify a band of 44 kDa of S1PR 1 or S1PR 3 in HUVEC, HTR-8/SVneo and BeWo cells (Fig. 1B) . Notably, S1PR 3 is expressed at very low level in HUVEC (Fig. 1B, right panel) . Unfortunately, anti-S1PR 2 antibody did not work for Western blotting. Blots were performed with a specific b-actin antibody and are shown as loading controls. Anti-S1PR 2 antibody could detect the expression of S1PR 2 protein in BeWo cells (Fig. 1C) .
The expression of S1P receptors in BeWo cells suggests a role of S1P-mediated regulation of BeWo cell functions.
S1P induces IL-6 secretion
We investigated whether S1P induces IL-6 secretion in BeWo cells. We measured the secretion of IL-6 in cell culture supernatants at different time points by using ELISA. We found that IL-6 secretion was maximally increased ( 5-fold; P , 0.0001) into the extracellular medium within 6 h after stimulation with S1P (1 mM) and then decreased to 50% until 24 h post activation ( Fig. 2A) . These results suggest that extracellular S1P triggered the IL-6 secretion in BeWo cells. To test whether S1P can induce the secretion of IL-6 in other trophoblast cell line, HTR-8/SVneo (HTR) cell line was taken as alternative model. Indeed, S1P could induce IL-6 secretion in HTR cells similar to BeWo cells. In control state, HTR cells secreted IL-6 at very low level (0.6 -1.5 pg/ml per 75 000 cells) in comparison with BeWo cells (5-7 pg/ml per 75 000 cells). The secretion of IL-6 was drastically increased ( 20-fold) within 6 h of S1P treatment (Fig. 2B ). These data suggest that S1P regulates IL-6 secretion in trophoblast cells.
To determine whether S1P-dependent IL-6 secretion was due to an effect on mRNA expression of IL-6 gene, we measured the expression of mRNA in control and S1P-activated BeWo cells by real-time PCR. As evident from Fig. 2C , the expression of IL-6 mRNA was slightly but not significantly (P . 0.05) affected after 6 h of S1P treatment and then was decreased to basal level within 12 h. Notably, the mRNA of IL-6 was significantly up-regulated ( 2-fold; P , 0.05) 24 h after S1P treatment.
In summary, stimulation of BeWo cells with S1P rapidly enhances the IL-6 protein secretion and also gene expression but at slower rate.
S1P induces IL-6 secretion via constitutive secretory pathway
The secretion of cytokines occurs primarily by two distinct pathways known as regulated (degranulation) and constitutive (recycling endosomes) (Stanley and Lacy, 2010) . Only the constitutive pathway is dependent on transcription events. In order to investigate whether the S1P-induced IL-6 secretion we observed in trophoblasts operated through the secretory pathway modulation, BeWo cells were pretreated for 1 h with ACD (1 mg/ml), an inhibitor of transcription, and then cells were stimulated with S1P. Pretreatment of cells with ACD drastically inhibited IL-6 secretion within 6 h after S1P activation (P , 0.0001; Fig. 3A, left panel) . This result indicates that IL-6 mRNA buffer and subjected for immunoblotting with specific anti-S1PR 1 or S1PR 3 antibodies. The 44 kDa band of S1PR 1 or S1PR 3 was detected in all cell types. S1PR 3 was expressed at very low level in HUVEC. b-actin blots are shown as loading controls. (C) BeWo cells were fixed and stained for S1PR 2 receptor protein with anti-S1P2/EDG5 monoclonal antibody (red, left panel) and for nucleus with Hoechst 33258 (blue, middle panel). The overlay is shown on the right panel. Pictures were taken at ×63 magnification. S1PR 2 regulates IL-6 secretion in BeWo cells might have a very short half-life. We performed a time course for IL-6 mRNA degradation after ACD treatment. Indeed, the expression of mRNA was rapidly degraded and reduced to 30% within 30 min after ACD treatment and then the rate of mRNA degradation became slower (Fig. 3A, right panel) . These data suggest that IL-6 secretion takes place via a constitutive secretory pathway in which cytokines are secreted within minutes or hours of protein synthesis. To confirm further, cells were treated with a protein synthesis inhibitor CHX (10 mg/ml). S1P-induced IL-6 secretion was completely inhibited in cells pretreated with CHX (Fig. 3B) suggesting that constitutive protein synthesis is required for secretion of IL-6. All together, these data suggest that IL-6 secretion occurs via a constitutive secretory pathway and continuous protein synthesis is essential for this process.
S1PR 2 receptor mediates S1P-induced IL-6 secretion in BeWo cells
We found that S1PR 2 was predominantly expressed in BeWo cells (Fig. 1A) . To examine whether S1PR 2 mediates S1P-induced IL-6 secretion, we used a selective S1PR 2 receptor antagonist JTE-013 (Osada et al., 2002) . BeWo cells were pretreated with JTE-013 (1 mM) for 30 min and then activated with S1P. The basal level of IL-6 secretion was significantly (P , 0.05) diminished after addition of JTE-013 alone (Fig. 4A) . S1P-induced IL-6 secretion after 6 h was markedly attenuated in the cells pretreated with JTE-013 (Fig. 4A) . To further confirm that S1PR 2 is indeed responsible for the S1P-induced IL-6 secretion, we knocked down the S1PR 2 gene by using siRNA pool. Four siRNAs directed against the different Figure 2 S1P induces IL-6 secretion in BeWo cells. 24 h before activation, 50 000 cells (BeWo or HTR-8/SVneo) were plated in 48-well plate and grown in factor-reduced medium (see Materials and Methods). Next day, cells were activated using respective basal cell media containing 0.5% depleted serum and 0.1% methanol (control) or S1P (1 mM) for the indicated time points. (A) IL-6 secretion in BeWo cells was quantified by ELISA. Bar diagram shows the relative secretion of IL-6 at different time points. (B) IL-6 secretion was measured in cell medium of control (no treatment), 0.1% methanol or S1P-treated HTR-8/SVneo and BeWo cells by ELISA. The concentration of IL-6 (pg/ml) was normalized against cell count (75 000 cells). (C) Total RNA of BeWo cells was isolated and the expression of IL-6 mRNA was measured by semi-quantitative real-time PCR. Bar diagram shows the fold changes of IL-6 transcripts at different time points after activation of BeWo cells with S1P. Data are means + SD of four independent experiments. ****P , 0.0001; ***P , 0.001; **P , 0.01. regions of S1PR 2 gene were used as a pool, which together downregulated S1PR 2 by 75 -85% at the level of transcription (data not shown). S1P-induced IL-6 secretion was significantly decreased in cells transfected with S1PR 2 -specific but not with non-specific siRNAs (Fig. 4B) . These data confirm that activation of S1P/S1PR 2 axis regulates IL-6 secretion in BeWo cells.
To rule out the involvement of other S1P receptor subtypes in IL-6 secretion, we used a specific agonist and antagonist of S1PR 1 and S1PR 3 . SEW2871, a selective agonist of S1PR 1 (Sanna et al., 2004) , could not induce IL-6 secretion up to 12 h after activation of cells at different concentrations (1 mM and 10 mM) (Fig. 4C) . Moreover, W146, the R enantiomer of a chiral S1PR 1 selective competitive antagonist, and W140, an inactive S enantiomer (Sanna et al., 2006) , did not affect the S1P-induced IL-6 secretion (Fig. 4D) . Similarly, a specific antagonist of S1PR 1 and S1PR 3 receptors VPC23019 (Davis et al., 2005) had no significant effects on S1P-induced IL-6 secretion (Fig. 4A) .
Taken together, these data suggest that S1PR 2 , but not other S1P receptor subtypes, exclusively regulates S1P-mediated IL-6 secretion in BeWo cells.
Rho/Rho-kinase activation is required for S1P-induced IL-6 secretion
In other cell types, S1P induces Rho GTPase through activation of S1PR 2 -coupled G 12/13 G-protein (Skoura and Hla, 2009 ). We wondered whether S1P/S1PR 2 -dependent activation of Rho/Rho-kinase pathway could be involved in regulating the IL-6 secretion. To block Rho/Rho-kinase pathway, we used a highly specific Rho-kinase Figure 3 ACD and CHX inhibit IL-6 protein secretion in Bewo cells. 24 h before activation, 50 000 BeWo cells were plated in 48-well plate and grown in factor-reduced medium (see Materials and Methods). Next day, cells were pretreated for 1 h with 1 mg/ml ACD, a transcription inhibitor, or with 10 mg/ml CHX, a protein synthesis inhibitor and then cells were stimulated with 0.1% of different solvents (methanol or DMSO) or S1P (1 mM) for 6 h. (A) Bar diagrams show the relative secretion of IL-6 protein into the medium (left panel). IL-6 secretion was significantly reduced in control and S1P-stimulated cells after pretreatment with ACD. Relative expression of IL-6 mRNA is shown at different time point after ACD treatment (right panel). IL-6 mRNA was rapidly degraded and reduced to 30% within 30 min after ACD treatment. (B) Relative expression of IL-6 secretion is shown from S1P-induced BeWo cells pretreated with or without CHX. IL-6 secretion was also significantly reduced in control and S1P-stimulated cells after pretreatment with ACD. Data are means + SD of three independent experiments with different passages of BeWo cells. ****P , 0.0001; *P , 0.05. S1PR 2 regulates IL-6 secretion in BeWo cells inhibitor Y27632 (20 mM). Cells were pretreated with Y27632 for 30 min and then activated with S1P (1 mM). The basal level of IL-6 secretion was significantly (P , 0.05) inhibited after addition of Y27632 alone (Fig. 5) . S1P-induced IL-6 secretion was significantly inhibited in cells pretreated with Y27632 (Fig. 5) . This data suggest that S1P activates Rho via S1PR 2 , and that downstream Rho-kinase activity is required for the activation of IL-6 secretion.
PI3K but not MAP-kinase activation mediates IL-6 secretion
Previous studies showed that S1PR 2 is able to activate PI3K and MAPkinases in various cell types (Gonda et al., 1999) . Other studies showed that PI3Ks regulate vesicular transport and cytokine secretion (Kim et al., 2008) . We investigated whether S1PR 2 -dependent activation of PI3K is involved in IL-6 secretion in BeWo cells. The cells were pretreated with LY294002, a specific inhibitor of PI3K 30 min before the activation of cells with S1P. The basal level of IL-6 secretion was drastically reduced in cells treated with LY294002 (50 mM) alone (P , 0.0001; Fig. 6A ). S1P-induced IL-6 secretion was markedly reduced in cells pretreated with LY294002 (Fig. 6A) . These data suggest that PI3K activation is required for IL-6 secretion. We asked whether PI3K is activated downstream of S1P/S1PR 2 axis and regulates S1P-induced IL-6 secretion. We measured the Akt phosphorylation at different time points. We found that the BeWo cells had a higher basal activation of PI3K that is not increased by S1P treatment Figure 4 S1PR 2 receptor mediates S1P-induced IL-6 secretion in BeWo cells. 24 h before activation, 50 000 BeWo cells were plated in 48-well plate and grown in factor-reduced medium (see Materials and Methods). Next day, cells were pretreated with different agonists and antagonists of S1P receptors for 30 min and then activated with S1P (1 mM) for 6 h. (A) Bar diagram shows that JTE-013 (1 mM), a selective S1PR 2 receptor antagonist, but not VP23019 (10 mM), a selective S1PR 1 and S1PR 3 receptor antagonist could inhibit the IL-6 secretion. The effects of different solvents (methanol and S1P) on IL-6 secretion are also shown. (B) Cell were transfected with control siRNA (Ko-siRNA) pool or S1PR 2 receptor specific siRNA pool and then activated with S1P (1 mM) 48 h of post transfection. The effect of S1PR 2 gene knockdown on IL-6 secretion is shown. (C) Cells were stimulated with S1P or SEW2871 (1 and 10 mM), a selective agonist of S1PR 1 receptor and then IL-6 secretion was measured at different time points. (D) Cells were pretreated with W140 (1.5 mM; inactive S enantiomer) and W146 (1.5 mM; active R enantiomer) and then stimulated with S1P. Bar diagram, relative expression of IL-6 secretion was quantified by ELISA. Data are means + SD of three independent experiments with different passages of BeWo cells. ****P , 0.0001; ***P , 0.001; *P , 0.05. (Fig. 6B) . The phosphorylation of Akt was not inhibited by JTE-013 (data not shown) suggesting that PI3K activity is required for IL-6 secretion independent of S1P/ S1PR 2 downstream signaling.
Various studies showed that S1PR 2 is able to activate extracellularsignal regulated kinases (ERKs) possibly by coupling with G i heterotrimeric G-protein complex (Skoura and Hla, 2009) . To investigate whether S1P-induced IL-6 secretion was regulated through the downstream activation of ERKs, BeWo cells were pretreated with a specific MEK1/2 inhibitor PD98059 that blocks the subsequent activation of ERK1/2. The basal level of IL-6 secretion was not significantly affected in cells treated with PD98059 (50 mM) for 6 h (Fig. 6A) . Similarly, pretreatment of cells with PD98059 was failed to inhibit the S1P-induced IL-6 secretion (Fig. 6A) . This result indicates that ERK1/2 activation is not required in downstream signaling of S1P/PI3K-dependent IL-6 secretion.
Activation of Rac1 regulates S1P-induced IL-6 secretion
Previous studies demonstrated that S1P activates Rac via G i coupling and its downstream signaling (Sugimoto et al., 2003) . We hypothesized that S1PR 2 might activate Rac possibly via coupling to G i . To investigate whether S1P-dependent IL-6 secretion was regulated through the downstream activation of Rac, cells were pretreated with the Rac1-specific inhibitor NSC23766 (IC 50 ¼ 50 mM) that blocks the Rac1 activation in vivo and in vitro (Pandey et al., 2009) . NSC23766 (200 mM) alone significantly reduced the basal level of IL-6 secretion to 55 + 5% (P , 0.05) at 6 h after cell treatment.
Furthermore, S1P-induced IL-6 secretion was significantly inhibited in cells pretreated with NSC23766 (Fig. 7) . These data indicate that Rac1 activation is required for S1P-induced IL-6 secretion.
Discussion
Regulation of IL-6 secretion during pregnancy is essential for maintaining the normal gestation. To our knowledge, this is the first report to show that S1P regulates the secretion of IL-6 in BeWo cells. Binding of S1P to S1PR 2 activates multiple downstream pathways that regulate the secretion. S1PR 2 leads to the activation of both Rho and Rac1 that regulate the IL-6 secretion.
Trophoblast cells isolated from fresh tissue have limited use to study specific function in vitro as they no longer proliferate in cell culture after isolation and spontaneously syncytialize in culture. Various studies Figure 5 Rho/Rho-kinase activation is required for S1P-induced IL-6 secretion. 24 h before activation, 50 000 BeWo cells were plated in 48-well plate and grown in factor-reduced medium (see Materials and Methods). Next day, cells were pretreated for 30 min with 20 mM Rho-kinase inhibitor Y27632 and then cells were stimulated with methanol (0.1%) or S1P (1 mM) for 6 h. The IL-6 secretion into the medium was measured by ELISA. Data are means + SD of three independent experiments with different passages of BeWo cells. **P , 0.01; *P , 0.05.
Figure 6 S1P-induced IL-6 secretion is regulated by PI-3 Kinase but not by MAP-Kinase. 24 h before activation, 50 000 BeWo cells were plated in 48-well plate and grown in factor-reduced medium (see Materials and Methods). Next day, cells were pretreated for 30 min with 50 mM PI-3 kinase inhibitor LY294002 or with 50 mM MEK1/2 inhibitor PD98059. (A) Cells were stimulated with S1P for 6 h. IL-6 secretion was measured by using ELISA. (B) Cells were incubated for 30 min with or without LY294002 (Ly) and then activated with S1P for different time points. Solvent (Methanol) was used as a control. Cell lysates were examined by Western blotting with specific phospho-Akt and Akt antibodies. Data are means + SD of three independent experiments with different passages of BeWo cells. ****P , 0.0001. S1PR 2 regulates IL-6 secretion in BeWo cells suggest that the choriocarcinoma cell line BeWo may serve as a good in vitro model of trophoblast cells (Orendi et al., 2011) . By RT PCR, it has been shown that S1PR 1 -3 are expressed in trophoblast cells isolated from term placenta (Johnstone et al., 2005) . In BeWo cells, S1P receptors were expressed similar to trophoblast cells. Furthermore, S1PR 2 is the major S1P receptor in BeWo cells as revealed by semi-quantitative real-time PCR.
Trophoblast is a cell type with endocrine functions that also secretes various cytokines throughout the gestation period (Denison et al., 1998; Bowen et al., 2002; Noyola-Martinez et al., 2013) . The knowledge about the role of S1P in regulating trophoblast functions is sparse and limited to trophoblast differentiation (Johnstone et al., 2005) . S1P has been shown to induce various cytokine secretions in different cell types (Kozawa et al., 1997; Oz-Arslan et al., 2006a; Oskeritzian et al., 2010) . In this study, we screened the effect of S1P on secretion of selected cytokines (IL -6, IL-8, IFN-g, CCL-2 and TNFa; data not shown) that are known to be expressed in trophoblast cells. We report that S1P exclusively regulates the secretion of IL-6 by trophoblast cells. Interestingly, our data show that S1P regulates IL-6 protein secretion in early phase (rapid) and gene expression in later phase (slow). In cancer cells, IL-6 regulates its own expression in an autocrine manner (Sansone et al., 2007) . STAT3, a transcriptional factor , activated via IL-6 enhanced the S1PR1 expression leading to IL-6 up-regulation (Lee et al., 2010) . Similarly the up-regulation of IL-6 gene in later phase after S1P treatment in these studies might be due to the autocrine action of secreted IL-6 protein. Both trophoblast and BeWo cells express the IL-6 receptor, IL6R and gp130 supporting the possibility of autocrine regulation of IL-6 (Nishino et al., 1990; Kojima et al., 1995) .
In mast cells, IL-6 is released via degranulation or vesicular secretion without degranulation (Kandere-Grzybowska et al., 2003; Stanley and Lacy, 2010) . IL-6 is trafficked and secreted directly as soluble protein.
In BeWo cells, IL-6 secretion was rapid and completely inhibited via inhibitor of transcription (ACD) or protein synthesis (CHX) suggesting that IL-6 protein is constitutively synthesized and released from BeWo cells. S1P modulates the vesicular secretory pathway. Of note, S1P did not affect the transcription of IL-6 gene significantly in early phase of activation, but it was enhanced within 24 h (Fig. 2B) . In contrast, ACD could block the secretion. The explanation for this may be the very short half-life of IL-6 mRNA, which was rapidly degraded within 30 min after ACD treatment (Fig. 3A, right panel) . In summary, constitutive synthesis but not storage of IL-6 is needed for secretion in BeWo cells and S1P modulates only the vesicular transport of IL-6.
Our study with specific S1PR 2 inhibitor JTE-013 and S1PR 2 silencing confirms that S1PR 2 might be the main S1P receptor that regulates IL-6 secretion in BeWo cells (Fig. 4) . S1PR 2 couples to G i , G q , as well as G 12/13 heterotrimeric G-proteins even though its coupling efficiency to the G 12/13 is much stronger (Ancellin and Hla, 1999; Windh et al., 1999) . Thus, coupling of diverse G-proteins to S1PR 2 suggests the activation of multiple downstream signaling pathways. Indeed, we found that binding of S1P to S1PR 2 activates multiple signaling pathways that regulate IL-6 secretion. In many cell types, binding of G 12/13 to S1PR 2 activates Rho/Rho-kinase pathway (Gonda et al., 1999; Lepley et al., 2005) . Indeed, we found that Rho-kinase activity is required for IL-6 secretion (Fig. 5) suggesting the activation of G 12/13 /Rho/Rho-kinase pathway downstream of S1PR 2 . Activation of Rho/Rho-kinase regulates actin dynamics via phosphorylating multiple cytoskeletal regulating proteins such as LIM-Kinases and MLC phosphatase (Ridley, 2006) . Our results suggest that S1P might induce constitutive secretion of IL-6 via regulating actin dynamics through S1PR 2 /Rho-kinase pathway.
Rac has been shown to stimulate granule exocytosis in mast cells but its role in constitutive exocytosis is not clear (Hong-Geller and Cerione, 2000) . Previous studies show that activation of Rho inhibits Rac (Sugimoto et al., 2003) . In contrast, we found that S1P activates both Rho/Rho-kinase and Rac1. A specific Rac1 inhibitor NSC23766 could block the S1P-induced IL-6 secretion. Rhodependent inhibition of Rac described in previous studies might be specific to cell migration and also dependent on cell types. In different cell types, G i is required for IL-6 and IL-8 secretion (Cummings et al., 2002; Oz-Arslan et al., 2006b) . In trophoblast cells, S1P regulates trophoblast differentiation through G i -pathway suggesting that S1P might activate G i -coupled S1P receptor (Johnstone et al., 2005) . We proposed that coupling of G i to S1PR 2 activates downstream target Rac1 leading to IL-6 secretion.
We showed that basal activity of PI3K is required for IL-6 that is not regulated by S1P/S1PR 2 axis. In other cell types, PI3K d regulates membrane fission of trans Golgi networks tubular carriers in selective cytokine secretion suggesting a role in constitutive secretory pathway (Lacy and Stow, 2011) . Our data suggest that PI3K activity is required but not sufficient for IL-6 secretion, and further required the activation of S1PR 2 receptor-mediated pathway.
Figure 7 S1P-induced secretion of IL-6 is regulated by the activation of Rac1. 24 h before activation, 50 000 BeWo cells were plated in 48-well plate and grown in factor-reduced medium (see Materials and Methods). Next day, cells were pretreated for 30 min with 200 mM NSC23766 (Rac1 inhibitor) and then stimulated with S1P (1 mM) for 6 h. IL-6 secretion of BeWo cells was measured using ELISA. Relative IL-6 secretion is shown in a bar diagram. Data are means + SD of three independent experiments with different passages of BeWo cells. ***P , 0.001; *P , 0.05.
Differential secretion of IL-6 has been observed in many pregnancy disorders, e.g. infertility, pre-eclampsia and preterm delivery (Prins et al., 2012) . A recent study showed that S1P inhibits trophoblast syncytialization and S1P secretion also decreased during this process (Singh et al., 2012) . Notably, in placenta, IL-6 mRNA expression decreases during syncytiotrophoblasts formation (Stephanou et al., 1995; Noyola-Martinez et al., 2013) . These studies support our findings that S1P-dependent IL-6 secretion might negatively regulate trophoblast differentiation. This study found that S1PR 2 -dependent signaling specifically regulates IL-6 secretion. Inhibitors of S1PR 2 could provide novel therapeutic options for treatment of IL-6 based disorders.
